Clinical trial / 2011
In patients with subclinical hypothyroidism, 16 mg soy phytoestrogens increased risk of overt hypothyroidism but reduced blood pressure, HOMA-IR, and hsCRP.
Sixty patients with subclinical hypothyroidism were randomly assigned to 8 weeks of 30 g soy protein with 2 mg phytoestrogens or 16 mg phytoestrogens, followed by an 8-week washout and crossover. Six female patients progressed to overt hypothyroidism after the 16-mg supplementation (standardized rate ratio 3.6; 95% CI, 1.9, 6.2). In addition, 16 mg phytoestrogens decreased systolic and diastolic blood pressure, insulin resistance (HOMA-IR: 3.5 ± 0.09 vs. 2.6 ± 0.08; P < 0.02), and hsCRP (4.9 ± 0.04 vs. 3.9 ± 0.03; P < 0.01), while lipid profiles remained unchanged.
- Study type
- Randomized, double-blind, crossover study
- Who was studied
- 60 patients with subclinical hypothyroidism
- What was measured
- Progression to overt hypothyroidism, blood pressure, insulin resistance, lipids, and hsCRP
THE PAPER
The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: a randomized, double-blind, crossover study.
Sathyapalan T, Manuchehri AM, Thatcher NJ, Rigby AS, Chapman T, Kilpatrick ES, Atkin SL. J Clin Endocrinol Metab, 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.